CNBC's Eamon Javers reports on Bill Ackman's stake in Allergan. Javers says this is a classic case of insider trading that is not against the rules.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
CNBC's Patti Domm discusses the amount of merger activity happening this week with a big three-way deal in the drug industry, and the $46 billion bid by Valeant and activist Bill Ackman for Allergan.
"Shark Tank" investor Kevin O'Leary discusses recent mergers between pharmaceutical companies.
CNBC's Meg Tirrell previews the earnings of biotech players Gilead and Amgen. Tirrell explains why investors will be focusing on Gilead's Sovaldi sales.
CNBC's Meg Tirrell; Herb Greenberg, CNBC contributor, and Arindam Nag, Mergermarket, discuss potential takeover targets in the pharmaceutical space.
Barbara Ryan, CNBC contributor, shares an inside look at what's happening among the drug giants as billion dollar deals are announced and big player reshape the industry.
These companies have a lot of money and are signaling what they plan to do going forward, reports CNBC's Meg Tirrell on the mega deals in big pharma.
CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss Valeant Pharmaceuticals bid for Allergan and why Valeant needed investor Bill Ackman involved in the deal.
Valeant Pharmaceuticals and Bill Ackman are proposing a cash-and-stock deal for Allergan that could be worth about $45 billion.
The "Squawk on the Street" news team discuss all the M&A activity going on in pharma after Novartis is reported to be purchasing GlaxoSmithKline's oncology products unit for $14.5 billion. Separately Novartis is selling its animal health division to Eli Lilly for $5.4 billion in cash.
The megabillion-dollar deals with Novartis also allow GlaxoSmithKline to "significantly expand" its world-leading vaccine business, GSK's CEO tells CNBC.
Eli Lilly Chairman & CEO John Lechleiter discusses his business' expansion of its animal health unit with the acquisition of Novartis' animal health business.
GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.
GlaxoSmithKline CEO Sir Andrew Witty, discusses the benefit to shareholders from his company's acquisition of Novartis' vaccination business, as well as its oncology unit.